My Watchlist

Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Recs

1

Today's Biotech Breakup

By | More Articles
November 30, 2012 | Comments (0)

BioCryst (Nasdaq: BCRX  ) announced today that it is canceling its merger with Presidio Pharmaceuticals, an event that Motley Fool health care analyst Brenton Flynn predicted could happen last month. With BioCryst's Hep-C candidate impaired, and companies like Abbott (NYSE: ABT  ) and Gilead  (NYSE: GILD  ) already light-years ahead in the race for an all-oral Hepatitis C regimen, it's easy to understand why a deal for Presidio and its phase-2-ready drug didn't make sense. 

With the impending spinoff of its branded-drug business, Abbott Labs is losing a massive blockbuster drug in Humira. It's a confusing event to understand, with many investors left wondering what to do with these two stocks once they're separated. To help investors better understand the upcoming event, the Fool has created a brand new premium report outlining both Abbott Labs and its spinoff, AbbVie. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this 2-for-1 report by clicking here now. 

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Brenton Flynn has no positions in the stocks mentioned above. David Williamson has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 2134922, ~/Articles/ArticleHandler.aspx, 5/25/2013 10:11:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 12 hours ago Sponsored by:
DOW 15,303.10 8.60 0.06%
S&P 500 1,649.60 -0.91 -0.06%
NASD 3,459.14 -0.28 -0.01%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/24/2013 3:59 PM
BCRX $1.59 Down -0.07 -4.22%
BioCryst Pharmaceu… CAPS Rating: *
GILD $55.81 Up +0.33 +0.59%
Gilead Sciences CAPS Rating: ****
AZN $3413.33 Down -13.17 -0.38%
AstraZeneca CAPS Rating: No stars
ABT $37.76 Up +0.28 +0.75%
Abbott Laboratorie… CAPS Rating: *****

Advertisement